China Reins In Cancer Drug Trials, Stressing Patient Needs and Benefits
Tougher Comparator Requirements
Executive Summary
China's drug regulatory authority is taking aim at strengthening randomized, controlled clinical trials conducted domestically for cancer drugs, leaving biotech stocks reeling from the proposed stricter requirements.
You may also be interested in...
China Oncology Drug Innovation Not Correlating With Clinical Benefit
While China approved a record number of innovative oncology drugs in 2021, the correlation between their novel mechanisms of action or targeted indication and clinical benefit is not statistically insignificant, a well-known researcher claims in a new report.
Lilly/Innovent Experience Show Hurdles Remaining For Chinese PD-1 Inhibitors
China has fielded several homegrown checkpoint inhibitors, using lower cost as an argument for the US market, but sintilimab – a key test case – has underscored FDA skepticism.
Chinese Firms At JPM Not About China, It’s Time To Go Global
From BeiGene to Innovent to Wuxi Biologics, executives at Chinese pharma firms are now discussing collaborations to go beyond China to become biopharma operations with a truly global presence.